

(DRAFT/UNAPPROVED)

**VIRGINIA BOARD OF PHARMACY
MINUTES OF STATEWIDE PROTOCOL WORK GROUP**

August 16, 2024

Department of Health Professions
Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233

CALL TO ORDER: A meeting of a work group created to discuss and review statewide protocols regarding the treatment of certain conditions was called to order at 1:50 PM.

PRESIDING: **Cheri Garvin**, RPh, Chair

MEMBERS PRESENT: **Shannon Dowdy**, PharmD, Virginia Board of Pharmacy
Patricia Richards-Spruill, RPh, Virginia Board of Pharmacy
Blanton Marchese, Virginia Board of Medicine
William Hutchens, MD, Virginia Board of Medicine
Krishna Madiraju, MD, Virginia Board of Medicine
Stephanie Wheawill, PharmD, Virginia Department of Health
Jenny Calhoun, RN, Virginia Department of Health

STAFF PRESENT: **William Harp**, MD, Executive Director, Virginia Board of Medicine
Caroline Juran, RPh, Executive Director, Virginia Board of Pharmacy
Erin Barrett, JD, Director of Legislative and Regulatory Affairs, DHP
Sorayah Haden, Executive Assistant, Virginia Board of Pharmacy

QUORUM With all members of the workgroup present, a quorum was established.

APPROVAL OF AGENDA: Agenda was approved as presented.

PUBLIC COMMENTS: Public comment was not provided.

REVIEW OF DRAFT AMENDMENTS OF THE HIV-PRP STATEWIDE PROTOCOL The work group reviewed and discussed the draft amendments to the HIV-PrEP statewide protocol to align with current CDC recommendations and include the injectable formulation Apretude®. Virginia Department of Health provided additional suggested edits to the draft protocol in the agenda packet via email. Ms. Juran revised the draft protocol to include VDH's suggested edits prior the meeting and provided a handout of the protocol for the work group to use during its discussion.
The following documents were reviewed:

- Draft amendments to Virginia’s HIV PrEP statewide protocol (handout)
- Virginia’s current HIV PrEP statewide protocol (in agenda packet)
- Oregon’s current HIV PrEP statewide protocol (in agenda packet)

MOTION

The work group unanimously voted to adopt the recommended draft amendments to the HIV PrEP statewide protocol as presented and amended as follows:

- **Pg. 7, 2A – Amend to state “If NO current HIV, HIV Ag/Ab Test non-reactive HIV, RNA test not detected, proceed”**
- **Pg. 7, 3 – Amend to state “Acute HIV symptoms:”**
- **Pg. 9, Hepatitis B Status – Amend to state “Do not start oral PrEP if has current Hepatitis B infection”**
- **Pg. 9 – Amend to state “Counsel on risk factors for Hepatitis B and recommend vaccination.”**
- **Pg. 9, Lipid panel – Amend to state “Order lab at intake and every 12 months for patients on F/TAF.”**
- **Pg. 9, Gonorrhea and Chlamydia Screenings – Amend to state “Urine test result”**
- **Pg. 11, 2 – Amend to state “Acute HIV symptoms:**
- **Pg. 11, 2 Symptoms – Amend to state “Counsel on acute HIV”**
- **Pg. 11, 3 Hepatitis B Vaccine – Amend to state “Confirmation of being fully vaccinated for Hepatitis B”.**
- **Pg. 12, Lipid panel – Amend to state “Order lab at intake and every 12 months for patients on F/TAF”.**
- **Pg. 12, Gonorrhea and Chlamydia Screenings – Amend to state “urine test result”**
- **Pg. 14, Lipid panel – Amend chart to reflect a requirement of oral PrEP labs every 12 months**
- **Pg. 14, Footnote 1 – Amend to state “HIV RNA is highly recommended at baseline, especially in certain situations, and if symptoms of possible acute HIV develop while taking PrEP.”**
- **Pg. 15, 6 – Amend to state “If no, pharmacist may prescribe oral PrEP for up to a 30-day supply.”**
- **Pg. 16, Syphilis – Amend to state “Order labs at initial intake and every 60-180 days depending on risk”.**
- **Pg. 16, Gonorrhea and Chlamydia – Amend to state “Order labs at initial intake and every 60-180 days depending on risk”.**
- **Pg. 16, HCG Pregnancy Test – Optional – Amend to state “Frequency: Every 2-12 months per patient’s preference and pharmacist clinical judgment”.**
- **Pg. 17, 2 – Amend to state “Acute HIV symptoms”**

(motion by Marchese, second by Hutchens)

**REVIEW ALL OTHER
CURRENT STATEWIDE
PROTOCOLS AND OFFER
RECOMMENDATIONS TO
AMEND, IF NECESSARY,
TO ENSURE
CONSISTENCY WITH
STANDARD OF CARE**

The work group reviewed and discussed all other current statewide protocols and offered recommendations to amend, if necessary, to ensure consistency with standard of care. Ms. Juran stated that the Board intends to review protocols annually for accuracy.

MOTION:

The work group unanimously voted to recommend amendments to the Pharmacist Protocol for Testing and Initiating Treatment for COVID-19 Virus Infection as follows:

- **Pg. 51 – Remove “Pursuant to the United States Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for the emergency use of PAXLOVID”**
- **Pg. 53 – Under “Patient Eligibility Screening”, delete “EUA” from “Paxlovid FDA EUA Fact Sheet”.**

No other amendments to statewide protocols were recommended. (motion by Marchese, second by Hutchens)

MEETING ADJOURNED:

Having completed all business on the agenda, the meeting was adjourned at 3:05 PM.

Caroline Juran
Executive Director

DATE: